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Summary
Suicidal thinking, self-harm and suicidal acts are common,
although determining their precise prevalence is complex.
Epidemiological work has identified a number of associated
demographic and clinical factors, though, with the exception of
past acts of self-harm, these are non-specific and weak future
predictors. There is a critical need shift focus from managing
‘suicidality-by-proxy’ through general mental health
treatments, to better understand the neuropsychology and
neurophysiology of such behaviour to guide targeted
interventions. The model of the cognitive control of emotion
(MCCE) offers such a paradigm, with an underlying
pan-diagnostic pathophysiology of a hypoactive prefrontal
cortex failing to suitably inhibit an overactive threat-responding
limbic system. The result is a phenotype – from any number
of causative gene–environment interactions – primed to
impulsively self-harm. We argue that such neural
dysconnectivity is open to potential therapeutic modification from
repetitive transcranial magnetic stimulation (rTMS). The current
evidence base for this is undoubtedly extremely limited, but the
societal and clinical burden self-harm and suicide pose warrants
such investigation.
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‘Blest are those/Whose blood and judgement are so well commingled/That they
are not a pipe for fortune’s finger/To sound what stop she please.’ – Shakespeare,
Hamlet, III, ii, 73
Globally, an estimated 5% of adults will attempt suicide at some
point in their life.1 Suicidal thinking and self-harm occur with
many mental states and include passive neglect, putting oneself
in risky situations, and many types of self-harm with varying
combinations of intent and threat to life. Inevitably such a
spectrum makes determining prevalence rates difficult, but typical
figures estimate self-harm occurs in up to about a fifth of
adolescents2 and over half of psychiatric in-patients.3
A helpful way of explaining self-harming is to invoke the
diathesis-stress model that proposes genetic, developmental and
temperamental factors constitute a diathesis disposition; and
acute environmental, social and psychological factors are situa-
tional stressors.4 Gender, age, ethnicity and religion5,6 early life7
and recent adverse events8 are associated factors in suicidal
thinking and acts. Problematically most of the identified risks
are common, non-specific, and of themselves reasonably weak
predictors of completed suicide.9–13 However, self-harm itself is
a strong predictor of future such behaviour it predicts adverse
outcomes in adolescents14; 16% of adults repeat self-harm within a
year (2% fatally so) and 7% die by suicide within 9 years.15
There is a need to move beyond descriptive epidemiology to
understand the mechanisms behind self-harm and suicidal acts.16
They are associated with high-risk decision-making, self-criticism,
sensitivity to social disapproval and an inability to use memory
and reflection about alternative positive outcomes of a stressful
situation. Neuropsychological work implicates deficits in impulse
control and curtailment of aggression,17–20 executive functioning
and emotional and affective regulation.21 These mechanisms are
found in many mental illnesses and are thus considered as pan-
diagnostic explanations for the emergence of suicidal acts and
thinking.4
Impulsivity and aggression: cognitive control
and restraint
A model of the cognitive control of emotion (MCCE) posits that
there are four stages in the production of an emotional response.22
First a stimulus, which could be external to an individual or an
internal thought or feeling, is perceived in a given environmental
and mental context, leading to a second process of applied
attention to this (or an attribute thereof), with some reduction
of attention to competing stimuli. A third step is the appraisal of
the stimulus with regard to an individual’s current needs or goals,
and finally varied expressions of emotional behaviour and
concomitant change in experience (Fig. 1).
A critical aspect of such a paradigm is the concept of control
of emotions. Several such strategies have been identified: situation
selection, namely choosing or avoiding emotionally salient stimuli;
situation modification, which attempts to alter a provoking
stimulus; attentional deployment, wherein either selective atten-
tion or distraction can be utilised to alter stimulus appraisal;
cognitive change that reappraises the way one views a stimulus;
and response modulation that attempts to change behaviour.
Although different approaches can thus be utilised in the control
of emotion, these will vary in degree and success between
experience type and magnitude, and between individuals in
response to similar stimuli.
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Neurophysiological research has implicated a frontolimbic
network in the MCCE, with phylogenetically more ancient
behaviours and emotions produced by subcortical limbic struc-
tures, whereas the prefrontal cortex (PFC) exerts vital ‘higher-level’
cognitive and executive control. Dysregulation of the frontolimbic
network, with a hypofunctioning ‘top-down’ control from the PFC
and an overactive limbic system results in poorer emotional
regulation with greater impulsivity and aggression.23 Fitting with
an aforementioned pan-diagnostic concept, such abnormalities have
been shown in borderline personality disorder,24 major depressive
disorder25 and bipolar affective disorder.26
Implicated limbic regions include the amygdala, the striatum,
the periaqueductal grey matter and the hypothalamus. These are
involved in modulating vigilance and threat perception, encoding
and learning from affective cues, initiating reactive aggression
through fight or flight responses23 and in generating negative
emotional states.27 The insula, which is anatomically deep in the
brain, receives strong amygdalar input and raises homeostatic and
visceral states to consciousness, particularly in powerful affective
states.28 All of these regions are richly interconnected, and have
strong reciprocal innervation with the PFC.
The roles of the PFC are numerous (see Table 1 for a
summary). It is critical in cognitive flexibility and the evaluation
and contextualisation of emotional states and environmental cues;
assaying the mental state of one’s self and others; determining the
degree of control one has over stressors; and making executive
decisions based on such information. Differential activation of
these neural circuits is compromised in suicidal thinking across
the diagnostic spectrum. This resonates with clinical observations
that patients are often unable to reflect, mentalise, take perspec-
tive, learn from experience and desist from impulsive acting out in
response to an adverse trigger that might be reminiscent of past
threats.
Available therapies, both psychological and pharmacological,
target these processes – with the aim of better controlling any
dysfunctional behaviour. This ‘systems neuroscience’ approach
offers a conceptual framework for integrating clinical observa-
tions, phenomenology, cognitive and neural processing and
pharmacological and psychological therapeutic approaches. It
also offers clinicians the opportunity to examine more contem-
porary mechanistic approaches that might lead to new therapies.
rTMS interventions: lessons from clinical data
Transcranial magnetic stimulation (TMS) is a non-invasive and
painless neuromodulatory tool that utilises Faraday’s law of
induction to alter underlying neuronal excitability, via a magnetic
coil that can be turned on and off at varying frequencies.29 So-
called ‘slow TMS’ (≤1 Hz) attenuates underlying cortical activity,




























Fig. 1 A model of the cognitive control of emotion, adapted from Ochsner et al.22 The top half of the ﬁgure shows the processes of emotional
responses in reaction to a stimulus (which can be external or an inner thought or feeling). The bottom half of the ﬁgure shows the cognitive
strategies that can be utilised to modify such responses.
Table 1 Prefrontal (PFC) and anterior cingulate (ACC) cortical
regions and major functions
23 ,28
PFC region Major functions
DLPFC Executive functioning; social cognition; working memory;
planning; cognitive flexibility; abstract reasoning; processing
the subjective experience of aroused emotional states,
including making unexpected emotional judgements
vmPFC Evaluating emotional states; integrating limbic emotional
drives with contextualising temporal lobe memory states;
coping and resilience through determination of control over
stressors
mPFC Theory of mind (mentalising) – evaluating the mental state
of others is on the dorsomedial aspect of the mPFC, self-
reflection of one’s own mental state on the ventral aspect
OFC Evaluating social and emotional cues; flexibly modifying
judgements; decision-making based on experience
ACC Conscious volitional reappraisal of the salience of strongly
emotional stimuli; regulating emotional responses
DLPFC, dorsolateral prefrontal cortex; vmPFC, ventromedial prefrontal cortex; mPFC,
medial prefrontal cortex; OFC, orbitofrontal cortex.
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with underlying cortical activity30 and through networks with
physiologically connected brain regions.31 Repetitive TMS (rTMS)
has been utilised clinically in the treatment of a variety of
psychiatric, psychological and neurological disorders, although at
this time it is only approved as a treatment for depression by the
US Food and Drug Administration (although not by National
Institute for Health and Care Excellence (NICE)).32
Impulsivity
There are several published investigations on the effects of rTMS
on suicidal thinking and impulsivity, although such work remains
quite preliminary at this time. One recent study applied an
intensive regimen of 10 Hz rTMS three times a day to the left
dorsolateral prefrontal cortex (DLPFC) for 3 days, in 377 in-
patients, achieving rapid improvements in suicidal ideation as
measured on the Beck Scale of Suicidal Ideation (SSI).33 However,
there were no differences compared with the sham arm. Another
study34 applied daily high-dose (6800-pulse) sessions of 10 Hz
rTMS, achieving rapid reductions in both depression symptoms
and SSI scores in 5–10 days; this was an uncontrolled case series
on just 19 patients, and suicidal ideation was a secondary outcome
measurement.
Regarding impulsivity, studies in healthy controls, utilising
varying rTMS parameters, have previously found that rTMS of the
right DLPFC (3 pulses delivered at 50 Hz, repeated every 200ms
for 40 s),35 left DLPFC (1Hz for 15min)36 or dmPFC (15 10-pulse
trains at 10Hz, with 10 s between trains)37 decreases impulsive
decision-making as measured on a delay discounting task; specific
effects on suicidality have not always been reported, and it remains
unclear whether the similar responses effected by stimulation of
varying sites is due the a generalisable effect on the PFC, or non-
specific effects of any intervention in a hard to treat group of
patients.
Borderline personality disorders
It is also of particular interest whether rTMS might offer a novel
and more effective therapeutic option for suicidality and impul-
sivity in traditionally challenging patient populations, such as
borderline personality disorder (BPD), although there has been far
less work in this group. Barnow and colleagues investigated several
different inhibitory and excitatory TMS parameters in 19 unme-
dicated women with BPD and 19 matched healthy control. They
showed an overall reduction in duration of the cortical silent
period (CSP) in the BPD group in the right cortex, suggesting a
deficit in intracortical inhibitions.38 Clinically, Arbabi et al39
described a case report where high-frequency rTMS was applied
to the left DLPFC (1500 10 Hz pulses in 30 trains of 5 s each, and
a 55-second inter-train intervals) of a 22-year-old woman for ten
sessions and they reported a resultant decrease in BPD symptom
severity (as measured by the Structured Clinical Interview for
DSM Disorders, 2nd edition (SCID-II); there was no change on
the Borderline Personality Disorder Severity Index (BPDSI)),
depression (measured with the Beck Depression Inventory) and
degree of impulsivity (measured with the Barratt Impulsiveness
Scale v11). The participant self-reported improvements in sleep,
emotional control, self-awareness of behaviour, sociability and
motivation for change following TMS. Functional neuroimaging
was undertaken before the first and after the last TMS session,
and again, 1 month later, with the application of the International
Affective Picture System that projected emotionally negative and
neutral images during scanning. The neuroimaging results fitted
with a frontolimbic dysconnectivity model, showing that rTMS
attenuated activation in the amygdala, superior temporal gyrus,
superior frontal gyrus, middle frontal gyrus and parahippocampus
when exposed to negative imagery; whereas post-rTMS the middle
temporal gyrus and post-central gyrus showed increased neural
activation to emotional stimuli.
An important feasibility study of rTMS on BPD, with some
interesting and positive findings, was reported by Cailhol et al.40
They undertook a randomised controlled study of high-frequency
rTMS (5-second bursts at 10 Hz, with 25-second between-train
intervals, for 20 min per day) on ten patients (nine completed
analyses, age range 20–45) with a DSM-IV-TR diagnosis of BPD.
The active group (n=5) received two sets of 5 days – separated
by a 2-day gap – of daily rTMS to the right-sided DLPFC. Those
in the sham group (n=4) received the same protocol but with
the coil tilted to 90° so avoiding any delivery to the patient. Two
of the active group and one of the sham demonstrated a response
of 30% reduction on the BPDSI,41 with statistically significant
improvements in the affective instability and anger subcompo-
nents of the BPDSI in the real group at 3 months. The active,
but not the sham group, also showed statistically significant
improvements in the Tower of London test – which assesses
planning – at the 3-month follow-up. The rTMS was well
tolerated by participants.
Shifting paradigms: moving to modulating
neurocognitive processing
There has generally been less direct testing of the impact of
neuromodulation on neurocognitive processing that might expli-
citly inform a neural circuitry model; understandably but pro-
blematically, the majority of work looks at clinical outcomes, and
existing work that does measure behavioural outcomes is inter-
esting but typically methodologically weak and with ill-defined
targeted neuropathophysiology. rTMS has been shown to affect
decision-making in paradigms investigating addictive behaviours,
at least in the laboratory. Low-frequency (inhibitory) rTMS to
the right DLPFC in healthy participants was shown to induce
risk-taking on a gambling paradigm,42 whereas high-frequency
(excitatory) rTMS to the left DLPFC can reduce food craving,43
cigarette smoking44 and cocaine craving45 compared with sham
TMS. More recently a pilot study by Taylor et al46 showed that
rTMS to the left DLPFC promoted resilience in healthy controls
during an aversive stimulus model of learned helplessness. These
studies indicate that rTMS can modulate behaviour and motiva-
tional states by enhancing or attenuating inhibitory prefrontal
mechanisms, although one is struck by the generally low participant
numbers and lack of attempted later replication. An interesting
general omission in the current literature has been the marked
lack of concomitant psychological, cognitive remediative or similar
intervention in parallel with neuromodulation. Neuromodulation
is principled on enhancing brain plasticity, and the potential for
this to augment other interventions appears inherently attractive;
Keefe et al47 proposed the evocative metaphor that neuronal
plasticity without parallel intervention was akin to consuming
protein without exercising.
Moving forward: from diagnosis to functional
neurobiological systems
The clinical problems of suicidal thinking, self-harm and suicide
scarcely need reiterating, highlighted by the World Health
Organization’s estimate48 of almost a million resultant deaths
annually. Despite the effectiveness of existing treatments, both
pharmacological and psychological, these problems are significant
and persistent, and can be chronic and disabling for many people.
What is striking is the juxtaposition between this reality and the
scientific literature that has focused relatively less on self-harm,
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tending to subsume it as an aspect of other mental illnesses rather
than viewing it as a problem unto itself, perhaps exemplified by
DSM-5 not having a code for suicidal behaviour. The resultant
clinical paradigm is that we tend to try to manage suicidality
by proxy: treat the background mental illness with the aim that
this will indirectly reduce the risks of self-harm, rather than see
self-harm as an expression of emotional dysregulation which, in
itself, is the cause of comorbid mental illness. Just as schizo-
phrenia, bipolar affective disorder and dementia have neuro‐
biological correlates and causes, so does suicidal thinking and
self-harm.
The existing rTMS work on depression, which constitutes a
large body of the neuromodulatory literature, focuses more
broadly on overall clinical improvement, with the major emphasis
on changes in mood symptoms. There has, however, been an
almost total neglect of the effects on impulsivity and self-harm.
Indeed a very recent consensus statement on rTMS by a group of
European experts49 does not even address self-harm as a current
or future target, although the earlier mentioned frontolimbic brain
circuitry is discussed in terms of mood regulation. There is
therefore a need and an opportunity to rectify this gap and move
towards translation of cognitive neuroscience activity into ther-
apeutic options.
The model presented here is of a brain phenotype that is
abnormally primed to misread threat perception, to have difficulty
with emotional regulation, and an increased propensity to greater
impulsivity: an individual predisposed to self-harm. Such a model
does not take specific aetiological factors into account (or the
relative importance of genes and environment), and sidesteps the
issues of causality (a hypoactive PFC leading to a hyperactive
limbic system or vice versa) and diagnosis; any combination of
such factors may be considered to have led to pathological
frontolimbic circuitry. Of course it can be reasonably argued that
this is a rather simplistic impulsivity-dysfunction model of a very
complex psychosocial problem, yet the role of promoting coping
and resilience to psychosocial adversity offers an alternative
perspective. A potentially important example is the psycholog‐
ical construct of an introjective-anaclitic dichotomy in differ-
entiating the extent to which a particular individual’s suicidal
ideation and actions are linked to a more internalised self-
criticism versus a more general set of expectations about others’
reactions within a social matrix: such factors can be measured,
and as earlier described existing neurobiological data tell us they
have differential neuroanatomical correlates. rTMS could offer
a tool to probe this and other such questions, and the lack of
diagnostic chains might therein be regarded as a strength of this
model.
It may be, and indeed would seem likely, that different groups
or populations might respond differently to such an intervention,
and, indeed, we argue that this is an attraction of this proposed
model: it presents eminently testable hypotheses to evaluate
coping strategies, impulsivity and cognitive models of self-harm,
and how rTMS might variously affect them, including in
attempting to delineate possible neurocognitive factors more or
less amenable to intervention. Undoubtedly many potential
difficulties may lie ahead, not least the pragmatics of costings,
time and acceptability of rTMS,50 on top of the fact that it remains
to be proven that such an intervention would prove effective.
Nevertheless, NICE and other large research bodies have asserted
the need for more research in specific patient groups, and for
trials of different dosages of rTMS. The opportunity cost of testing
such a hypothesis would currently appear to outweigh that of
inaction.
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